Prostate Cancer Roundtables
The panel concludes with a discussion on how recent Medicare Part D reforms have capped patient out-of-pocket costs.
The panel transitions to role of bone-protecting agents, highlighting the importance of baseline DEXA scans.
The panel weighs some more nuanced decision-making for selecting among androgen receptor pathway inhibitors.
The panel delves into the nuanced decision-making around using doublet versus triplet systemic therapy in mHSPC.
The panel considers the challenges of applying trial data based on conventional imaging to today's PSMA PET-guided staging.
The panel explores the decision-making around offering RP to patients with borderline or undetected mHSPC on PSMA PET.
The panel discusses the role of PSMA PET imaging in staging and managing mHSPC, highlighting insurance barriers and more.
The panel highlights key ASCO GU 2025 data, including TALAPRO-2, PSMA PET, the PORTOS score, and emerging therapies like EZH2
The panel discusses data from PEACE-3 and maintaining ARSI therapy with emerging combination treatments.
The experts discuss treatment selection in mHSPC and share insights from STOPCAP and ARANOTE on ARSI use in older patients.
The panel covers metastasis-directed therapy and trials including SWOG 1802 in oligometastatic prostate cancer.
The panelists examine biomarker adoption challenges and the impact of PSMA PET on staging and treatment decisions.
Experts discuss advances in biomarker testing, treatment intensification, and the impact of TALAPRO-2 in prostate cancer care
The panel highlights the limitations of conventional imaging in detecting disease progression at undetectable PSA levels.
The panel zooms in on the use of radium, enzalutamide, and other therapeutic agents, touching on patient preference trials.
The panel focuses on decision-making between AR antagonists and abiraterone, weighing factors such as reimbursement.
The panel goes in-depth on the use of testing and SBRT as metastasis-directed therapy in newly diagnosed prostate cancer.
The panel explores the the role of imaging, genomics, and patient factors in the management of mHSPC.
In the final segment, the panel emphasizes the importance of trust in the patient-provider relationship.
The panel exchanges strategies on sequencing and debates the potential of immunotherapy in prostate cancer.
In part four, the panel shares thoughts on the implications of recent trials including ARASENS, ARANOTE, and PEACE-3.
The panel discusses nuances to consider when using PSMA PET imaging, including differentiating false positives.
Experts discuss managing prostate cancer progression, risk stratification, and balancing treatment with quality of life.
Expert panel discusses diagnostic criteria, precision medicine, and PSMA imaging in managing metastatic prostate cancer.
The panel explores the distinct roles of alpha and beta emitters in radiopharmaceutical therapy for prostate cancer care.
The expert panel discusses emerging biomarkers and treatment combinations for CRPC and mHSPC.
The evolving role of RLT and radium-223 in managing metastatic mHSPC and CRPC is discussed.
The panel examines the impact of the latest data from ARANOTE and PEACE-3 in part three of this roundtable.
The panelists discuss key considerations for patient selection in doublet and triplet therapies for mHSPC and CRPC.
In part one of this roundtable, the panel discusses advances in imaging and tailored treatment strategies for prostate cancer
In part six of this roundtable series, the panelists finish their discussion by reviewing immunotherapy in prostate cancer.
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
In part four of this roundtable series, the panelists discuss CRPC and the typical patterns of presentation.
Part three of this roundtable delves into genomic biomarkers and the use of doublet and triplet therapies for mHSPC.
Part two of the roundtable series explores ADT and novel hormonal therapies for patients with prostate cancer.
Part one of a roundtable series on prostate cancer, focusing on defining mHSPC and mCRPC.
The final segment of this roundtable series discusses radiopharmaceuticals and PARP inhibitors.
Part five of this roundtable series covers data and insights from the ARANOTE and PEACE 3 trials.
Part four of a PCa roundtable series focuses on the effectiveness of ADT with triplet therapy.
Part three of this prostate cancer roundtable covers prognostic factors such as Gleason scores and genomic assays.
Part two of this roundtable features a discussion on the role of bone scans compared to the newer PSMA PET scans.
The first part of this roundtable focuses on the impact of recent research on clinical practice.
In the final segment of our roundtable series, the panelists discuss the treatment of CRPC, focusing on metastatic disease.
In the fifth segment of our roundtable series, the treatment of patients with CRPC is discussed.
In the fourth part of our series, the panelists discuss PROs and potential patient comorbidities.
In the third part of this series, disparities and the optimization of care is discussed, along with the use of ADT and ARPIs.
In the second segment of our roundtable series, the panelists discuss their approaches to the use of PSMA PET for patients.
In the first part of this series, the panel discusses treatments in the post-salvage setting and review therapeutic options.
Experts at ESMO Congress 2024 discuss novel therapies for castration-resistant prostate cancer.
Experts review the CONTACT-02 trial as well as the Decipher score utilized in the STAMPEDE trial.
The roundtable of experts discuss the realities of the SPLASH trial's hazard ratio and overall survival results.
At ESMO 2024, experts discuss androgen-deprivation therapy in HSPC as well as the ARANOTE trial.
Experts at ESMO 2024 discuss the implications and insights associated with the Peace III trial.
Experts discuss mHSPC discuss risk stratification, developed novel approaches for treatment, and treatment sequencing.
The panel concludes with thoughts on the evolving landscape of PC treatment, focusing on multidisciplinary collaboration.
Future Directions in Metastatic PC: Exploring Monotherapy, Novel Therapies, and Strategic Sequencing
The panel ponders the future of metastatic prostate cancer treatment, emphasizing the potential of emerging therapies.
The panel considers the decision-making process for chemo eligibility in mHSPC, emphasizing the role of patient education.
Implementing Triplet Therapy for mHSPC: Collaboration, Patient Communication, and QOL Considerations
The panel delves into triplet therapy for mHSPC, highlighting the benefits and logistics of the ARASENS regimen.
The panel shares insights on managing mHSPC, emphasizing patient communication and evolving role of novel therapies.
The panel explores the challenges involved in managing mHSPC, focusing on difficulties with obtaining PSMA scans.
Panel experts discuss PSMA-targeting agents currently being assessed, including PSMA-I&T-Lutetium-177.
Dr. Oliver Sartor and Dr. Rana McKay discuss some limitations (and advantages) of lutetium-177-PSMA.
Dr. Oliver Sartor weighs in on lutetium-177-PSMA as an effective therapy for prostate cancer.
The palliative benefits of lutetium-177 PSMA are discussed, including reduced symptom burden compared with standard of care.
Drs. George and Sprenkle discuss PSMA PET scans, including challenges and the potential of Lutetium-based PSMA treatments.
The panel discusses lutetium-177-PSMA for the treatment of advanced prostate cancer and reviews the VISION trial.
Drs. Agarwal, Calais, and Tward discuss the use of radiopharmaceutical-based therapeutics in patients with prostate cancer.
Drs. Agarwal and Tagawa discuss the VISION trial and how lutetium-177 PSMA-617 will be used to treat metastatic CRPC.
Drs. Agarwal and Tagawa discuss PSMA imaging and the future of CT scans in the follow-up of metastatic prostate cancer.
Drs. Agarwal and Tward discuss the use of PSMA imaging for oncologists and urologists dealing with localized prostate cancer.
Drs. Agarwal and Calais review the basics of PSMA imaging of prostate cancer and what makes it unique.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.